2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Generative AI, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, CLL, Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2625 Improving patient engagement and provider confidence in CAR T-cell therapy for DLBCL and FL through a collaborative learning model in community oncology settings

Michael D. Jain, MD, PhD, Sairah Ahmed, MD2, Joshua D. Brody, MD3, Emily Zyborowicz, MPH4, Jeffrey Carter5, Chelsie Anderson Chadha6, Laura Simone, PhD7, Shelby Sullivan, PharmD8
1 Moffitt Cancer Center, Tampa, Florida, United States
2 UT MD Anderson Cancer Center, Houston, Texas, United States
3 Ruttenberg Treatment Center of The Tisch Cancer Institute at Mount Sinai, New York, New York, United States
4 PRIME Education, New York, New York, United States
5 PRIME Education, New York, New York, United States
6 PRIME Education, New York, New York, United States
7 PRIME Education, New York, New York, United States
8 PRIME Education, New York, New York, United States

Background:
Community oncology teams face barriers to timely patient identification, referral, and shared decision-making (SDM) for chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). To address these gaps, a quality improvement (QI) initiative leveraging PRIME’s Collaborative Learning Model was executed to enhance patient understanding of CAR T-cell therapy, while optimizing timely, community-based integration of CAR T-cell therapy for eligible patients.

Methods:
This multi-component QI initiative included baseline provider surveys (N=48), 4 audit-feedback (AF) sessions with multidisciplinary care teams (N=42), patient-provider collaborative learning sessions (provider N=23, patient/caregiver N=42), and clinic champion follow-up surveys (N=9) across 4 community oncology clinics. AF sessions identified workflow gaps in CAR T-cell eligibility, referral, care coordination, and patient engagement. Participating clinics also conducted provider-led patient education sessions on CAR T-cell therapy, including logistics, adverse events (AEs), and SDM. A SDM resource developed for this initiative was introduced during both components. Assessments evaluated provider knowledge, confidence, competency, workflow changes, and patient understanding, engagement, and SDM participation.

Results:
Baseline provider surveys identified key barriers to CAR T-cell-eligible patient identification and engagement, including logistical considerations (56%), gaining insurance approval (41%), limited staffing, resources, and experience (23%), and line-of-therapy eligibility (21%). Additional barriers to SDM included patients’ low health literacy (23%), low confidence engaging in SDM (19%), and insufficient time for SDM discussions (17%).

Provider identified goals of AF sessions included standardizing identification of eligible patients, improving communication with referral centers, implementing AE management plans, and expanding patient/caregiver education. Following participation, high/very high confidence in identifying eligible patients improved from 49% pre-activity to 73% post-activity and confidence engaging patients in SDM improved from 51% to 73%. Planned practice changes including educating team members on current evidence/guidelines (81%), improving referral coordination (42%), designating CAR T champions (31%), and increasing patient education efforts (29%). Post-session, 67% of providers planned to use the SDM resource to support SDM and improve patient identification for CAR T-cell therapy.

Collaborative sessions improved patient understanding and provider commitment to CAR T-cell-related education and SDM. Among patients, ratings of good/very good understanding of CAR T-cell therapy benefits improved from 14% pre-session to 100% post-session, while understanding of the referral/manufacturing process improved from 41% to 97%. High/very high patient confidence in voicing treatment preferences increased from 38% to 90%. Among providers, the proportion who reported discussing CAR T-cell therapy with eligible patients “most/all of the time” increased from 31% pre-session to 75% post-session, similarly the proportion reporting “frequent/always” engaging patients in SDM increased from 48% to 63%.

On follow-up survey, clinic champions reported sustained practice-level improvements, including earlier eligible patient identification (56%) and patient education and expectation-setting (33%). Additionally, 89% of clinic champions reported high/very high confidence in identifying eligible patients for CAR T-cell therapy. Teams implemented standardized screening protocols, patient identification checklists, dedicated CAR T clinical teams, and standardized workflows to improve communication.

Conclusions:
This QI initiative demonstrated that collaborative, team-based educational interventions can improve provider confidence, patient engagement, and workflows supporting timely identification of eligible patients with DLBCL and FL for CAR T-cell therapy in community oncology settings. Persistent barriers highlight ongoing opportunities for future systems-based educational initiatives to support equitable and evidence-based CAR T-cell integration into community practice.

Study Sponsor Statement
The study was supported by an educational grant from Bristol Myers Squibb and Novartis Pharmaceuticals Corporation, who had no role in the study design, execution, analysis, or reporting.

Michael D. Jain, MD, PhD: Pagona Health - Current equity holder in publicly-traded company; Prime Education - Honoraria; Curio Science - Honoraria; OncLive - Honoraria; Decera - Honoraria; Kite/Gilead - Research Funding; Lilly - Research Funding; Incyte - Research Funding; BMS - Consultancy (Includes expert testimony); Legend - Consultancy (Includes expert testimony); Myeloid Therapeutics - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony); Arcellx - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony)